[Retracted] The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta‐Analysis
D Li, M Li, H Li, P Shi, M Chen, T Yang - Disease Markers, 2023 - Wiley Online Library
Objective. To assess the use of cytotoxic drugs as first‐line chemotherapy for nonsquamous
non‐small‐cell lung cancer (NSCLC) with EGFR mutation. Method. This study uses the …
non‐small‐cell lung cancer (NSCLC) with EGFR mutation. Method. This study uses the …
Experience with erlotinib in the treatment of non-small cell lung cancer
L Landi, F Cappuzzo - Therapeutic Advances in Respiratory …, 2015 - journals.sagepub.com
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths. In
the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has …
the last decade, the epidermal growth factor receptor (EGFR) signalling pathway has …
Results from a phase I safety lead-in study investigating the combination of erlotinib and the histone deacetylase inhibitor entinostat in patients with advanced NSCLC
K Konduri, AI Spira, RM Jotte, T Boyd… - Journal of Clinical …, 2009 - ascopubs.org
e14545 Background: Preclinical studies showed the synergistic effect of entinostat with
epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI) in NSCLC cell lines …
epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI) in NSCLC cell lines …
Beyond the TRIBUTE trial: integrating HER1/EGFR tyrosine kinase inhibitors with chemotherapy in advanced NSCLC
M Reck - 2006 - Future Medicine
Evaluation of: Herbst RS, Prager D, Hermann R et al.: TRIBUTE: a Phase III trial of erlotinib
hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in …
hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in …
[PDF][PDF] Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice
O Fiala, M Pesek, J Fínek, J Krejci, J Ricar… - Neoplasma, 2013 - researchgate.net
Median PFS in patients who were observed with rash during the treatment was 3.0 vs. 1.2
months in patients with no rash (p< 0.001), median of OS in patients who were observed …
months in patients with no rash (p< 0.001), median of OS in patients who were observed …
Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC
L Paz‐Ares, D Soulieres, J Moecks… - Journal of Cellular …, 2014 - Wiley Online Library
Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …
Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)
WS Siegel-Lakhai, JH Beijnen, JHM Schellens - The oncologist, 2005 - academic.oup.com
The CME activity for this article is forthcoming. Access and take the CME test online and
receive 1 hour of AMA PRA category 1 credit at CME. TheOncologist. com Gefitinib (Iressa®; …
receive 1 hour of AMA PRA category 1 credit at CME. TheOncologist. com Gefitinib (Iressa®; …
Erlotinib for first line treatment in unselected patients (p) with advanced or metastatic non-small cell lung carcinoma (NSCLC)
U Jimenez, A Gurpide, D Isla… - Journal of Clinical …, 2007 - ascopubs.org
7639 Background: Erlotinib is an orally available selective EGFR tyrosine-kinase inhibitor.
Erlotinib is approved for the treatment of patients (p) with advanced or metastatic NSCL that …
Erlotinib is approved for the treatment of patients (p) with advanced or metastatic NSCL that …
Tyrosine kinase inhibition of EGFR: A successful history of targeted therapy for NSCLC since 20 years
J Vansteenkiste, E Wauters - Annals of Oncology, 2018 - annalsofoncology.org
The first-in-human dosing of the Epidermal Growth Factor Receptor tyrosine kinase inhibitor
(EGFR-TKI) ZD1839 (later gefitinib) goes back to April 1998, by now almost 20 years ago. In …
(EGFR-TKI) ZD1839 (later gefitinib) goes back to April 1998, by now almost 20 years ago. In …
Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC
W Brugger, N Triller, M Blasinska-Morawiec… - Journal of Clinical …, 2009 - ascopubs.org
8020 Background: The SATURN (BO18192) study investigated whether erlotinib
maintenance therapy improved PFS in patients (pts) with advanced NSCLC who had …
maintenance therapy improved PFS in patients (pts) with advanced NSCLC who had …